Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Breast-conserving surgery in the neoadjuvant setting

D R Brenin1, M Morrow

  • 1Department of Surgery, Northwestern University Medical School, Chicago, IL, USA.

Seminars in Oncology
|May 5, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands.

British journal of clinical pharmacology·2025
Same author

Radioactive seed localization is a safe and effective tool for breast cancer surgery: an evaluation of over 25,000 cases.

Journal of radiological protection : official journal of the Society for Radiological Protection·2024
Same author

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Discovery of over 200 new and expanded genetic conditions using GeneMatcher.

Human mutation·2022
Same author

Robotic mastectomy: the next major advance in breast cancer surgery?

The British journal of surgery·2021
Same author

Use of an ultrasound imaging device within the applicator to evaluate placement and support treatment planning for breast brachytherapy and intraoperative radiation therapy.

Brachytherapy·2020
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Neoadjuvant chemotherapy for operable breast cancer shows tumor regression but not improved survival. Current evidence suggests it remains investigational, with no clear survival benefit demonstrated over standard treatments.

Area of Science:

  • Oncology
  • Breast Cancer Research
  • Chemotherapy Studies

Background:

  • Neoadjuvant chemotherapy for operable breast cancer is debated.
  • While effective for tumor regression, its impact on survival is unclear.

Purpose of the Study:

  • To evaluate the survival benefits of neoadjuvant chemotherapy in operable breast cancer.
  • To assess the long-term oncological outcomes and breast conservation rates.

Main Methods:

  • Analysis of a large prospective trial with 5-year disease-free survival data.
  • Comparison between neoadjuvant chemotherapy followed by locoregional treatment versus locoregional treatment followed by adjuvant chemotherapy.

Main Results:

  • No significant difference in 5-year disease-free survival was observed between the treatment arms.

Related Experiment Videos

  • Data on overall survival from key trials (e.g., NSABP B-18) are still pending.

    • Conclusions:

    • Neoadjuvant chemotherapy's role in improving survival for operable breast cancer is not yet established.
    • Long-term data on local recurrence risk after neoadjuvant-induced downstaging and breast conservation therapy are needed.
    • Current use of neoadjuvant chemotherapy for operable breast cancer should be considered investigational.